UNSPSC 51393402: Bamifylline

This classification denotes a bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZTY15D026H. European Medicines Agency schedules Bamifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06097MIG. Bamifylline generally arises in the molecular formula C20H27N5O3. The term BAMIFYLLINE is an International Non-Proprietary Name or INN. BAMIFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule bamifylline under HS 29395900 and SITC 54145. As of Q4 2014, BAMIFYLLINE remains the US FDA Preferred Term for this commodity. Bamifylline bears US NLM identifiers UMLS ID C0052945 and NCI Concept Code C76573. SMILES: O=C1N(C(=O)N(C2NC(N(CCN(CCO)CC)C12)CC1CCCCC1)C)C.

UNSPSC 51393402 Bamifylline is a Commodity code whose nominal scope — a respiratory stimulant pharmaceutical — does not align with the state and local procurement activity currently tagged to it. The recent opportunities show no actual solicitations for bamifylline; instead, the code captures unrelated pharmaceutical and prescription-management procurements, including naloxone acquisition and direct-to-manufacturer prescription programs. State and local governments are not actively buying bamifylline under this code at present.

The two recent opportunities illustrate the mismatch. Seminole County, Florida issued an IFB (IFB60459723LAS, posted June 30, 2026, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a county health building—an opioid-reversal agent wholly distinct from bamifylline's therapeutic category. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, seeking information on contracting models and fulfillment capacity outside traditional pharmacy benefit manager and wholesaler channels—a procurement infrastructure question unrelated to any single active pharmaceutical ingredient. The code shows limited recent state and local activity, and the activity present does not reflect bamifylline procurement. Firms pursuing opportunities under this code should verify the actual pharmaceutical or service scope against the UNSPSC assignment before committing resources.